Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6410991 | 0.90 | TACR1 (0.43) | TACR1SIGMAR1GRIN1GRIN2BDRD2 | |
| SCHEMBL6406919 | 0.84 | TACR1 (0.51) | TACR1SIGMAR1GRIN1GRIN2BDRD2 | |
| SCHEMBL6413716 | 0.80 | TACR1 (0.54) | TACR1KMT2A | |
| SCHEMBL6409793 | 0.77 | BRD4 (0.41) | SIGMAR1DRD2DRD3KMT2ACYP1A2 | |
| SCHEMBL1617423 | 0.72 | TACR1 (0.56) | TACR1SIGMAR1GRIN1GRIN2BCYP1A2 | |
| SCHEMBL24036210 | 0.72 | TACR1 (0.62) | TACR1SIGMAR1GRIN1GRIN2BCYP1A2 | |
| SCHEMBL6943959 | 0.72 | TACR1 (0.62) | TACR1SIGMAR1GRIN1GRIN2BCYP1A2 | |
| SCHEMBL731081 | 0.72 | TACR1 (0.62) | TACR1SIGMAR1GRIN1GRIN2BCYP1A2 | |
| SCHEMBL16836134 | 0.72 | SIGMAR1 (0.64) | TACR1SIGMAR1GRIN1GRIN2BCYP1A2 | |
| SCHEMBL467266 | 0.72 | TACR1 (0.62) | TACR1SIGMAR1GRIN1GRIN2BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038072-A1 | Nitrogeneous cyclic ketone derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2005-02-17 | — | — | US | disclosed |
| EP-1460062-A1 | NITROGENOUS CYCLIC KETONE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038072-A1 | Nitrogeneous cyclic ketone derivative, process for producing the same, and use | BDKRB1, BDKRB2, TACR1 | TACR1 3/4885SIGMAR1 72/4885GRIN1 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.